Prospective Non-Interventional Study Comparing Osimertinib +/- Chemotherapy for EGFR-Mutated NSCLC Patients

Key facts

Sponsor

PrECOG, LLC.

Principal Investigator

Suzanne Cole, MD

UT Southwestern Simmons Comprehensive Cancer Center

Intervention

Osimertinib(drug)

Enrollment

538 target

Eligibility

18 years · All sexes

Timeline

2024 – 2029

Study locations (30)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• Mercy Clinic Fort Smith Communities, Fort Smith, Arkansas, United States
• Mercy Research, Fort Smith, Arkansas, United States
• Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
• Stanford Cancer Center Emeryville, Emeryville, California, United States
• Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
• Stanford Cancer Center South Bay, San Jose, California, United States
• John Muir Health, Walnut Creek, California, United States
• Bayhealth, Dover, Delaware, United States
• Satellite of Bayhealth Sussex, Milford, Delaware, United States
• Sibley Johns Hopkins University, Washington D.C., District of Columbia, United States
• Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: Liberty County Cancer Care, Hinesville, Georgia, United States
• Lewis Cancer and Research Pavilion at Saint Joseph's/Candler: Regional Cancer Care, Jesup, Georgia, United States
• Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia, United States
• Advocate Good Shepherd Hospital, Barrington, Illinois, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

ECOG-ACRIN Cancer Research Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Small cell lung cancer

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1, PHASE2NCT06694454
  Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
  National Cancer Institute (NCI)
• RECRUITINGNANCT07398599
  Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study
  Second Affiliated Hospital of Nanchang University
• RECRUITINGPHASE1, PHASE2NCT07480213
  Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)
  Beijing Biotech
• RECRUITINGPHASE1, PHASE2NCT07227597
  A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
  Merck Sharp & Dohme LLC
• RECRUITINGPHASE1NCT07348211
  First in Human Study of SIM0610 in Solid Tumors
  Jiangsu Simcere Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07161310
  Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
  Goethe University
• RECRUITINGPHASE2NCT07304739
  Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
  Tianjin Medical University Cancer Institute and Hospital
• RECRUITINGPHASE1, PHASE2NCT06956690
  A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
  Hummingbird Bioscience

See all trials for Small cell lung cancer →